Sigyn Therapeutics, Inc.
SIGYOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $143,322 |
| Operating income | −$2.5M | −$2.5M | −$2.1M | −$2.0M | −$916,434 | −$517,958 |
| Net income | −$3.3M | −$4.1M | −$2.9M | −$3.0M | −$1.3M | −$3.1M |
| Total assets | $213,719 | $321,806 | $332,879 | $710,259 | $694,082 | $642,145 |
| Total liabilities | $4.7M | $3.7M | $2.2M | $974,843 | $594,903 | $3.1M |
| Equity | −$4.5M | −$3.4M | −$1.9M | −$264,584 | $99,179 | −$2.5M |
| EPS (diluted) | $-2.51 | $-3.77 | $-3.13 | $-0.08 | — | — |
| Shares out. | 1.2M | 42.7M | 37.3M | 35.2M | 93.3M | 81.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- 74.9%
- Return on assets
- −1562.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 2185.7%
- Debt / equity
- —
- Book value / share
- $-3.64
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -445.17distress
- Accruals / assets
- −1154.7%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Segelman JosephOfficer — Chief Executive Officer | Jun 23, 2017 | Buy | 8,500 | $0.18 |
| Segelman JosephOfficer — CEO | Mar 29, 2017 | Buy | 2,500 | $0.12 |
| Segelman JosephOfficer — CEO | Dec 19, 2016 | Buy | 5,000 | $0.10 |
| Segelman JosephOfficer — CEO | Dec 14, 2016 | Buy | 5,000 | $0.10 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2,735 | 1.0 | -86.4% |
| Apr 30, 2026 | 20,045 | 1.0 | +660.7% |
| Apr 15, 2026 | 2,635 | 1.0 | 0.0% |
| Mar 31, 2026 | 2,635 | 1.0 | -91.0% |
| Mar 13, 2026 | 29,321 | 1.0 | +30764.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity saleFeb 20, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Other material eventAug 15, 2025
- Director / officer change · Regulation FD disclosureMar 7, 2025
- Director / officer changeJan 16, 2025
- Amended charter or bylawsJan 6, 2025
- Unregistered equity saleOct 16, 2024
- Unregistered equity saleOct 7, 2024
- Other material eventJun 6, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.